Smoking Reduces Effectiveness of Neoadjuvant Therapy in Pancreatic Cancer

Understanding the Study
Researchers found that smoking affects how well neoadjuvant therapy (NAT) works in treating pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC). Neoadjuvant therapy is given before surgery to shrink the tumor. This study explored the impact of smoking on this treatment.

Key Findings

1. Lower Major Responses: Smokers showed fewer major responses to NAT (13.7%) compared to non-smokers (30.4%). This means the therapy was less effective in shrinking the tumor in smokers.
2. Pathologic Complete Responses: Only 2.1% of smokers achieved a complete response, while 9.9% of non-smokers did. A complete response means no signs of cancer were found in the tissue after therapy.
3. Survival Rates: Non-smokers had a median overall survival of 39.1 months compared to 26.6 months for smokers.

Why It Matters
Smoking has long been known as a risk factor for many cancers, including pancreatic cancer. This study shows that smoking not only increases the risk of developing cancer but also reduces the effectiveness of treatments like NAT. This can lead to poorer outcomes for patients who smoke.

What Patients Can Do

• Quit Smoking: If you are a smoker and diagnosed with pancreatic cancer, quitting smoking can improve the effectiveness of your treatment and overall survival. Seek support from healthcare providers to quit smoking.
• Discuss with Your Doctor: Talk to your oncologist about your smoking history. They may adjust your treatment plan to give you the best possible outcome.

Conclusion
Smoking significantly reduces the effectiveness of neoadjuvant therapy in pancreatic cancer patients. Quitting smoking can improve treatment responses and survival rates. This highlights the importance of smoking cessation for better cancer treatment outcomes.

Source For more detailed information, refer to the original study: here